Warren is the former senior science editor of TheBody.com and TheBodyPRO.com. He started out as an editorial intern in 2008.
He has been awarded journalist fellowships from the HIV Research for Prevention conference, and the Logan Science Journalism program.
He is a member of the Association of Health Care Journalists, the National Association of Science Writers, Science Writers in New York, and Asian American Journalists Association.
Warren is a native New Yorker, born in Manhattan and raised in Queens.
Follow Warren on Twitter: @WarrenAtTheBody.
Warren does not have any disclosures or conflicts of interest to report, as of June 20, 2017.
Categories Covered:HIV Treatment Strategies, FDA-Approved HIV Medications, Efavirenz (Sustiva, Stocrin), Abacavir (Ziagen), Tenofovir Disoproxil Fumarate (Viread), Doravirine (Pifeltro), Etravirine (Intelence), Rilpivirine (Edurant), Ibalizumab (Trogarzo), Adverse Events, Comorbidities, and HIV, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Cobicistat/Emtricitabine/Elvitegravir/Tenofovir Alafenamide (Genvoya, E/C/F/TAF), Providing Quality HIV Care, HIV Treatments in Development, PrEP (HIV Pre-Exposure Prophylaxis), Pregnancy, Childbirth, and HIV, HIV Policy and Advocacy, HIV Education and Risk Management, HIV Prevention Methods, HIV Epidemiology, First-Line HIV Treatment, HIV Care and Services Outside the US, Managing People Newly Diagnosed With HIV, HIV Care Continuum, Dolutegravir (Tivicay), Managing HIV Drug Resistance, Switching or Stopping HIV Treatment, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), HIV Testing, Managing Long-Term HIV Survivors, HIV Case Management and Social Work, Meeting the Costs of HIV Care, Emtricitabine/Rilpivirine/Tenofovir Alafenamide (Odefsey), Emtricitabine (FTC, Emtriva), Primary Care of People With HIV, HIV Basic Science and Pathogenesis, Emtricitabine/Tenofovir Alafenamide (Descovy), Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Lopinavir/Ritonavir (Kaletra), Lamivudine (3TC, Epivir), Cobicistat/Darunavir (Prezcobix), HIV, Discrimination, and Law, Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF), Atazanavir/Cobicistat (Evotaz), Pediatric HIV Care, Managing Primary/Acute HIV Infection, PEP (HIV Post-Exposure Prophylaxis), HIV and Mental Health Care
This week, a study finds that increased muscle area after starting HIV treatment may be due to fat accumulation within the muscle rather than new muscle formation.
This week, a study finds that abstinence-only programs continue to be ineffective at keeping young people from having sex, and censor valuable information on HIV prevention.
This week, a study finds that the average time it takes to for newly diagnosed patients to enter care is three months.
This week, a study review finds that early interventions in monkeys, such as broadly neutralizing antibodies, can help lead to viral suppression without treatment.
This week, a study finds that injectable cabotegravir, an investigational integrase inhibitor, is well tolerated and shows promise as pre-exposure prophylaxis (PrEP).
This week, a study finds that viral load perception may change sexual behaviors among HIV-positive men who have sex with men.
This week, a study finds a new key step in how HIV binds to CD4 cells, which could lead to the development of new HIV drugs.
PrEP (pre-exposure prophylaxis) is highly effective at preventing HIV, but uptake has been slow around the world. We asked providers and community leaders what they thought needed to happen for PrEP to reach everybody who needs it.
This week, a study finds that administering two broadly neutralizing antibodies very early on during infection helped monkeys achieve long-term viral suppression of simian HIV (SHIV).